Aurinia Pharmaceuticals (NASDAQ:AUPH) Cut to Buy at StockNews.com

StockNews.com downgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a strong-buy rating to a buy rating in a report issued on Wednesday morning.

Aurinia Pharmaceuticals Price Performance

AUPH stock opened at $7.93 on Wednesday. The firm’s fifty day moving average is $8.33 and its 200 day moving average is $7.68. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. Aurinia Pharmaceuticals has a 52 week low of $4.71 and a 52 week high of $10.67. The firm has a market cap of $1.13 billion, a P/E ratio of -52.83 and a beta of 1.22.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. CWM LLC boosted its stake in shares of Aurinia Pharmaceuticals by 247.7% during the third quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 8,180 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Aurinia Pharmaceuticals by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 10,700 shares during the last quarter. Segall Bryant & Hamill LLC grew its position in shares of Aurinia Pharmaceuticals by 1.6% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company’s stock worth $4,125,000 after buying an additional 9,031 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Aurinia Pharmaceuticals during the third quarter valued at approximately $3,330,000. Finally, Intech Investment Management LLC bought a new position in shares of Aurinia Pharmaceuticals during the third quarter valued at approximately $262,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.